{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T23:52:42Z","timestamp":1780098762899,"version":"3.54.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s11892-024-01543-5","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T08:01:59Z","timestamp":1716883319000},"page":"167-172","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Exploring the Interplay between Diabetes and Lp(a): Implications for Cardiovascular Risk"],"prefix":"10.1007","volume":"24","author":[{"given":"Corral","family":"Pablo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrupe","family":"Mat\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusto","family":"Lavalle Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gimenez","family":"Sergio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renna Nicol\u00e1s","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"issue":"39","key":"1543_CR1","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346. https:\/\/doi.org\/10.1093\/eurheartj\/ehac361.","journal-title":"Eur Heart J"},{"issue":"9","key":"1543_CR2","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","volume":"80","author":"S Tsimikas","year":"2022","unstructured":"Tsimikas S, Marcovina SM. Ancestry, Lipoprotein(a), and Cardiovascular Risk Thresholds: JACC Review Topic of the Week. J Am Coll Cardiol. 2022;80(9):934\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2022.06.019.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"1543_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1136\/heartjnl-2021-320708","volume":"109","author":"SA Di Fusco","year":"2022","unstructured":"Di Fusco SA, Arca M, Scicchitano P, Alonzo A, Perone F, Gulizia MM, Gabrielli D, Oliva F, Imperoli G, Colivicchi F. Lipoprotein(a): a risk factor for atherosclerosis and an emerging therapeutic target. Heart. 2022;109(1):18\u201325. https:\/\/doi.org\/10.1136\/heartjnl-2021-320708.","journal-title":"Heart"},{"issue":"1","key":"1543_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40119-024-00353-w","volume":"13","author":"H Thau","year":"2024","unstructured":"Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024;13(1):39\u201367. https:\/\/doi.org\/10.1007\/s40119-024-00353-w.\u00a0","journal-title":"Cardiol Ther"},{"issue":"1","key":"1543_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/17446651.2023.2293108","volume":"19","author":"D Tsamoulis","year":"2024","unstructured":"Tsamoulis D, Kosmas CE, Rallidis LS. Is inverse association between lipoprotein(a) and diabetes mellitus another paradox in cardiometabolic medicine? Expert Rev Endocrinol Metab. 2024;19(1):63\u201370. https:\/\/doi.org\/10.1080\/17446651.2023.2293108.","journal-title":"Expert Rev Endocrinol Metab."},{"key":"1543_CR6","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Lamina C, Ward NC. Lipoprotein (a) and diabetes mellitus. Atherosclerosis. 2022 ;349:63\u201371. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.016. (This review aims to shed light on the most recent findings of epidemiological and Mendelian Randomisation studies regarding the inverse association between Lp(a) and risk of prevalent and incident diabetes.)","DOI":"10.1016\/j.atherosclerosis.2022.04.016"},{"issue":"7","key":"1543_CR7","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.3390\/jcm12072529","volume":"12","author":"SA Di Fusco","year":"2023","unstructured":"Di Fusco SA, Maggioni AP, Scicchitano P, Zuin M, D\u2019Elia E, Colivicchi F. Lipoprotein (a), Inflammation, and Atherosclerosis. J Clin Med. 2023;12(7):2529. https:\/\/doi.org\/10.3390\/jcm12072529.","journal-title":"J Clin Med"},{"issue":"4","key":"1543_CR8","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1194\/jlr.R061648","volume":"57","author":"SM Marcovina","year":"2016","unstructured":"Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. J Lipid Res. 2016;57(4):526\u201337. https:\/\/doi.org\/10.1194\/jlr.R061648.","journal-title":"J Lipid Res"},{"issue":"6","key":"1543_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1161\/01.atv.16.6.713","volume":"16","author":"HG Kraft","year":"1996","unstructured":"Kraft HG, Lingenhel A, K\u00f6chl S, et al. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16(6):713\u20139. https:\/\/doi.org\/10.1161\/01.atv.16.6.713.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"19","key":"1543_CR10","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","volume":"55","author":"S Erqou","year":"2010","unstructured":"Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55(19):2160\u20137. https:\/\/doi.org\/10.1016\/j.jacc.2009.10.080.","journal-title":"J Am Coll Cardiol"},{"key":"1543_CR11","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.04.013","volume":"349","author":"C Lamina","year":"2022","unstructured":"Lamina C. Mendelian Randomization: Principles and its usage in Lp(a) research. Atherosclerosis. 2022;349:36\u201341. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.04.013.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1543_CR12","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s40001-022-00825-6","volume":"27","author":"S Wang","year":"2022","unstructured":"Wang S, Zha L, Chen J, Du D, Liu D, Zhong M, Shang R, Sun D, Sun C, Jin E. The relationship between lipoprotein(a) and risk of cardiovascular disease: a Mendelian randomization analysis. Eur J Med Res. 2022;27(1):211. https:\/\/doi.org\/10.1186\/s40001-022-00825-6.","journal-title":"Eur J Med Res"},{"key":"1543_CR13","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Kronenberg F. Lipoprotein(a): from Causality to Treatment. Curr Atheroscler Rep. 2024;26(3):75\u201382. https:\/\/doi.org\/10.1007\/s11883-024-01187-6 (This paper reviews the evidence why lipoprotein(a) (Lp(a)) is a causal risk factor for cardiovascular disease and how high Lp(a) concentrations should be managed now and with an outlook to the future.)","DOI":"10.1007\/s11883-024-01187-6"},{"issue":"6562","key":"1543_CR14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1126\/science.abg8289","volume":"373","author":"RE Mukamel","year":"2021","unstructured":"Mukamel RE, Handsaker RE, Sherman MA, Barton AR, Zheng Y, McCarroll SA, Loh PR. Protein-coding repeat polymorphisms strongly shape diverse human phenotypes. Science. 2021;373(6562):1499\u2013505. https:\/\/doi.org\/10.1126\/science.abg8289.","journal-title":"Science"},{"key":"1543_CR15","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","volume":"16","author":"E Paige","year":"2017","unstructured":"Paige E, Masconi KL, Tsimikas S, Kronenberg F, Santer P, Weger S, Willeit J, Kiechl S, Willeit P. Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovasc Diabetol. 2017;16:38.","journal-title":"Cardiovasc Diabetol"},{"key":"1543_CR16","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","volume":"56","author":"S Mora","year":"2010","unstructured":"Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252\u201360.","journal-title":"Clin Chem"},{"key":"1543_CR17","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","volume":"42","author":"A Langsted","year":"2021","unstructured":"Langsted A, Nordestgaard BG, Kamstrup PR. Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study. Eur Heart J. 2021;42:1147\u201356.","journal-title":"Eur Heart J"},{"issue":"4","key":"1543_CR18","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jacl.2023.05.103","volume":"17","author":"I Skoumas","year":"2023","unstructured":"Skoumas I, Andrikou I, Grigoriou K, Dima I, Lazarou E, Vlachopoulos C, Tsioufis K. Lipoprotein(a), metabolic profile and new-onset type-2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study. J Clin Lipidol. 2023;17(4):512\u20138. https:\/\/doi.org\/10.1016\/j.jacl.2023.05.103.","journal-title":"J Clin Lipidol"},{"issue":"3","key":"1543_CR19","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","volume":"1","author":"PR Kamstrup","year":"2013","unstructured":"Kamstrup PR, Nordestgaard BG. Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study. Lancet Diabetes Endocrinol. 2013;1(3):220\u20137. https:\/\/doi.org\/10.1016\/S2213-8587(13)70064-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"1543_CR20","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1373\/clinchem.2017.277103","volume":"63","author":"A Tolbus","year":"2017","unstructured":"Tolbus A, Mortensen MB, Nielsen SF, Kamstrup PR, Bojesen SE, Nordestgaard BG. Kringle IV Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 Repeats. Clin Chem. 2017;63(12):1866\u201376. https:\/\/doi.org\/10.1373\/clinchem.2017.277103.","journal-title":"Clin Chem"},{"issue":"2","key":"1543_CR21","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MCO.0000000000000994","volume":"27","author":"KM Kostner","year":"2024","unstructured":"Kostner KM, Kostner GM. The 10 essential questions regarding lipoprotein(a). Curr Opin Clin Nutr Metab Care. 2024;27(2):136\u201343. https:\/\/doi.org\/10.1097\/MCO.0000000000000994.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"1543_CR22","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Ward NC, Vickneswaran S, Watts GF. Lipoprotein (a) and diabetes mellitus: causes and consequences. Curr Opin Endocrinol Diabetes Obes. 2021 Apr 1;28(2):181\u2013187. https:\/\/doi.org\/10.1097\/MED.0000000000000597. (This review provides an update on the role of lipoprotein (a) [Lp(a)] in diabetes, including its impact as a risk factor as well as its contribution to the development of cardiovascular disease.)","DOI":"10.1097\/MED.0000000000000597"},{"issue":"14","key":"1543_CR23","doi-asserted-by":"publisher","first-page":"1337469","DOI":"10.3389\/fendo.2023.1337469","volume":"15","author":"M Li","year":"2024","unstructured":"Li M, Wang Y, Yao Q, Liang Q, Zhang Y, Wang X, Li Q, Qiang W, Yang J, Shi B, He M. Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes. Front Endocrinol (Lausanne). 2024;15(14):1337469. https:\/\/doi.org\/10.3389\/fendo.2023.1337469.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"1543_CR24","doi-asserted-by":"publisher","first-page":"147916412311971","DOI":"10.1177\/14791641231197114","volume":"20","author":"MS GholamiChahkand","year":"2023","unstructured":"GholamiChahkand MS, EsmaeilpourMoallem F, Qezelgachi A, Seifouri K, PesaranAfsharian A, Sheikhzadeh F, Poursalehi A, FaniSadrabadi FS, SaghabTorbati M, Ramezanzade M, Alishiri G, Ansari A, ZareDehabadi E, KarimiMatloub S, Sheikh Z, Deravi N, Mehrtabar S, Chichagi F, FaalHamedanchi N, Arzaghi M, Asadi M, AlsadatDadkhah P, Ansari A. Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review. Diab Vasc Dis Res. 2023;20(6):14791641231197114. https:\/\/doi.org\/10.1177\/14791641231197114.","journal-title":"Diab Vasc Dis Res"},{"issue":"3","key":"1543_CR25","doi-asserted-by":"publisher","first-page":"106117","DOI":"10.1016\/j.isci.2023.106117","volume":"26","author":"P Wang","year":"2023","unstructured":"Wang P, Yuan D, Zhang C, Jia S, Song Y, Tang X, Zhao X, Gao R, Xu B, Yuan J. Association between cumulative lipoprotein(a) exposure and adverse cardiovascular outcomes in patients with prediabetes or diabetes. iscience. 2023;26(3):106117. https:\/\/doi.org\/10.1016\/j.isci.2023.106117.","journal-title":"iscience."},{"issue":"4","key":"1543_CR26","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2217\/clp.12.46","volume":"7","author":"Q Qi","year":"2012","unstructured":"Qi Q, Qi L. Lipoprotein(a) and cardiovascular disease in diabetic patients. Clin Lipidol. 2012;7(4):397\u2013407. https:\/\/doi.org\/10.2217\/clp.12.46.","journal-title":"Clin Lipidol"},{"issue":"8","key":"1543_CR27","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.2337\/dc19-1398","volume":"43","author":"K Littmann","year":"2020","unstructured":"Littmann K, Wodaje T, Alvarsson M, Bottai M, Eriksson M, Parini P, Brinck J. The Association of Lipoprotein(a) Plasma Levels With Prevalence of Cardiovascular Disease and Metabolic Control Status in Patients With Type 1 Diabetes. Diabetes Care. 2020;43(8):1851\u20138. https:\/\/doi.org\/10.2337\/dc19-1398.","journal-title":"Diabetes Care"},{"key":"1543_CR28","doi-asserted-by":"publisher","unstructured":"\u2022 Thau H, Neuber S, Emmert MY, Nazari-Shafti TZ. Targeting Lipoprotein(a): Can RNA Therapeutics Provide the Next Step in the Prevention of Cardiovascular Disease? Cardiol Ther. 2024 Mar;13(1):39\u201367. https:\/\/doi.org\/10.1007\/s40119-024-00353-w. (This comprehensive review, provide a detailed overview of RNA-based therapeutic approaches and discuss the recent advances and challenges of RNA therapeutics specifically designed to reduce Lp(a) levels and thus the risk of cardiovascular disease.)","DOI":"10.1007\/s40119-024-00353-w"},{"issue":"4","key":"1543_CR29","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/ATVBAHA.119.310961","volume":"39","author":"AM Schmidt","year":"2019","unstructured":"Schmidt AM. Diabetes Mellitus and Cardiovascular Disease. Arterioscler Thromb Vasc Biol. 2019;39(4):558\u201368. https:\/\/doi.org\/10.1161\/ATVBAHA.119.310961.","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-024-01543-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11892-024-01543-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-024-01543-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T06:26:57Z","timestamp":1718951217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11892-024-01543-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["1543"],"URL":"https:\/\/doi.org\/10.1007\/s11892-024-01543-5","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"15 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human And Animal Rights And Informed Consent"}}]}}